From pulsed-field ablation to non-invasive monitoring, this was an exciting year for cardiac device tech.
Here are the top 10 cardiac device stories from MassDevice and its sister sites:
10. Medtronic to pay Acutus $17M following EU MDR submission of left-heart access portfolio
Earlier this year, Acutus agreed to sell its left-heart access portfolio to Medtronic for $50 million.
9. Abbott confirms first implants of its dual-chamber leadless pacemaker system
The company designed its i2i technology to provide beat-by-beat communication between two leadless pacemakers, with one positioned on the right ventricle and the other in the right atrium.
8. Boston Scientific completes $1.75B Baylis Medical acquisition
The deal expanded Boston Scientific’s electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms. It also gained a family of guidewires, sheaths and dilators used to support left heart access.
7. What is pulsed-field ablation? Here’s what you need to know
Top experts at Boston Scientific, Medtronic and Acutus Medical shared insights about pulsed-field ablation’s potential in the cardiac device space at this year’s DeviceTalks Boston.
6. Abbott says study backs Amplatzer Amulet against Boston Scientific’s Watchman
The prospective, international, multi-center Amulet IDE trial was the largest randomized left atrial appendage (LAA) occlusion study to date, Abbott said. A year before, Boston Scientific released data that it said demonstrated that its next-generation Watchman FLX stroke prevention device outperformed the Amulet device.
5. iRhythm wants to be a $1 billion a year company in 5 years
Company officials think iRhythm’s wearable heart monitoring tech could serve millions more patients, tripling company revenue to more than $1 billion by 2027.
4. Cordis to acquire MedAlliance for an initial $235M
MedAlliance has coronary and peripheral artery treatment devices, including its sustained sirolimus drug-eluting balloon, Selution SLR.
3. Edwards launches Sapien 3 Ultra Resilia heart valve following FDA approval
The next-gen TAVR incorporates the company’s Resilia tissue technology.
2. Medtronic moves forward with Affera pulsed-field ablation tech
It completed enrollment and final treatment in the Sphere Per-AF pivotal trial to study Affera’s pulsed-field ablation catheter tech. Medtronic closed its $1 billion acquisition of Affera in August.
1. Johnson & Johnson completes $16.6B Abiomed acquisition
“The completion of this acquisition allows Johnson & Johnson MedTech to expand our portfolio in the high-growth cardiovascular markets, adding solutions for heart recovery to our global market-leading Biosense Webster electrophysiology business.”